Latigo Biotherapeutics Stock Forecast

Stock Price Forecast

According to 4 analysts polled by S&P Global, Latigo Biotherapeutics stock has a consensus rating of "Strong Buy" and an average price target of $52.25. The average 1-year stock price forecast is 254.00% higher than the current stock price, while the lowest is $36 (+143.90%) and the highest is $73 (+394.58%).

Price Target: $52.25 (+254.00%)

Analyst Consensus: Strong Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$36	$52.25	$50	$73
Change	+143.90%	+254.00%	+238.75%	+394.58%

* Price targets were last updated on Sep 2, 2026.

Analyst Ratings

The average analyst rating for Latigo Biotherapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart

Rating	Sep '26	Oct '26
Strong Buy	4	4
Buy	0	0
Hold	0	0
Sell	0	0
Strong Sell	0	0
Total	4	4

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Yatin Suneja Guggenheim	Guggenheim	Buy Initiates $50	Buy	Initiates	$50	+238.75%	Sep 2, 2026
Akash Tewari Jefferies	Jefferies	Buy Initiates $50	Buy	Initiates	$50	+238.75%	Sep 1, 2026
Salveen Richter Goldman Sachs	Goldman Sachs	Buy Maintains $73	Buy	Maintains	$73	+394.58%	Sep 1, 2026

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

n/a

EPS This Year

-2.18

EPS Next Year

-2.09

from -2.18

Fiscal Year	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	-
Operating Income	-63.45M	-110.39M	-145.44M
Net Income	-61.18M	-109.17M	-142.60M
EPS	-	-	-2.18
No. Analysts	-	-	4

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	n/a
Avg	n/a
Low	n/a

Revenue Growth

Chart

Revenue Growth	2027	2028
High	-
Avg	-
Low	-

EPS Forecast

Chart

EPS	2026	2027	2028
High	-2.18
Avg	-2.18
Low	-2.18

EPS Growth

Chart

EPS Growth	2027	2028
High	-
Avg	-
Low	-